Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Beckton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

Established in 1984, the China Anti-Cancer Association (CACA) is a non-government and non-profit organisation with a mission to unite people involved in all branches of oncology with a shared interest in fighting cancer. CACA is dedicated to improving cancer control in China through increasing the survival rates, and decreasing the incidence and mortality rates of cancer. CACA plays an important role in promoting academic exchange, organising public education, establishing collaboration with international cancer societies, and providing data and advice to the Chinese government for making strategies and policies on cancer control. The branches consist of 45 professional societies, 47 full membership organisations, and 30 local anti-cancer associations with a total membership exceeding 47,000.

The German Cancer Society (DKG) is the largest scientific and specialist oncology company in Germany with headquarters in Berlin. They are engaged in cancer care on the basis of evidence-based medicine, interdisciplinary and consequent quality standards. In total, DKG has about 7600 members, organised in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. Since cancers need to be cross-treated and researched, their members are not only medical doctors of all sections, but also basic researchers, medical technical assistants, nurses, psychologists and other professionals who work on cancer.

DKG specialises in certification of oncological care institutions, development of clinical practice guidelines, coordination of guidelines in the framework of the German Guideline Program of Oncology (GGPO), development and transfer of oncological knowledge, and improvement of information given to patients.

Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.